Follow-Up of Alcohol Septal Ablation for Symptomatic Hypertrophic Obstructive Cardiomyopathy. The Baylor and Medical University of South Carolina Experience 1996 to 2007

JACC: Cardiovascular Interventions

Volumn 1, Issue 5, 2008, Pages 561-570

  Fernandes, Valerian L ^a   Nielsen, Christopher ^a   Nagueh, Sherif F ^b   Herrin, Amy E ^c   Slifka, Christine ^a   Franklin, Jennifer ^b   Spencer III, William H ^a  

^a MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

^b HOUSTON METHODIST RESEARCH INSTITUTE   (United States)

^c MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

Author keywords

alcohol; cardiomyopathy; hypertrophy

Indexed keywords

ALCOHOL;

ADOLESCENT; ADULT; AGED; ANGINA PECTORIS; ARTERY DISSECTION; ARTICLE; ARTIFICIAL HEART PACEMAKER; CATHETER ABLATION; CONTROLLED STUDY; DYSPNEA; ECHOCARDIOGRAPHY; EXERCISE; FEMALE; FOLLOW UP; HEART EJECTION FRACTION; HEART LEFT VENTRICLE OUTFLOW TRACT; HEART LEFT VENTRICLE PRESSURE; HEART VALVE SURGERY; HEART VENTRICLE INFARCTION; HEART VENTRICLE SEPTUM; HEART VENTRICLE WALL; HUMAN; HYPERTROPHIC OBSTRUCTIVE CARDIOMYOPATHY; LONGITUDINAL STUDY; MAJOR CLINICAL STUDY; MALE; MITRAL VALVE REGURGITATION; MUSCLE RESECTION; PRIORITY JOURNAL; SUDDEN DEATH; SURVIVAL RATE; SYMPTOMATOLOGY; TREATMENT OUTCOME;

ADULT; AGED; ANEURYSM, DISSECTING; ANGINA PECTORIS; BALLOON DILATATION; CARDIAC PACING, ARTIFICIAL; CARDIOMYOPATHY, HYPERTROPHIC; CORONARY ANEURYSM; DYSPNEA; ECHOCARDIOGRAPHY, DOPPLER; ETHANOL; EXERCISE TOLERANCE; FEMALE; FOLLOW-UP STUDIES; HEART BLOCK; HEART CATHETERIZATION; HEART VALVE PROSTHESIS IMPLANTATION; HUMANS; INJECTIONS, INTRA-ARTERIAL; KAPLAN-MEIERS ESTIMATE; MALE; MIDDLE AGED; MITRAL VALVE INSUFFICIENCY; PROSPECTIVE STUDIES; SOUTH CAROLINA; TEXAS; TIME FACTORS; TREATMENT OUTCOME; VENTRICULAR FUNCTION, LEFT;

EID: 54049088131     PISSN: 19368798     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jcin.2008.07.005     Document Type: Article

References (38)

1. Maron B.J., Bonow R.O., Cannon R.O., et al. Hypertrophic cardiomyopathy: interrelations of clinical manifestations, pathophysiology, and therapy: part 1. N Engl J Med 316 (1987) 780-789
2. Maron B.J., Bonow R.O., Cannon R.O., et al. Hypertrophic cardiomyopathy: interrelations of clinical manifestations, pathophysiology, and therapy: part 2. N Engl J Med 316 (1987) 844-852
3. Wigle E.D., Rakowski H., Kimball B.P., and Williams W.G. Hypertrophic cardiomyopathy: clinical spectrum and treatment. Circulation 92 (1995) 1680-1692
4. Maron B.J., Mathenge R., Casey S.A., Poliac L.C., and Longe T.F. Clinical profile of hypertrophic cardiomyopathy identified de novo in rural communities. J Am Coll Cardiol 33 (1999) 1590-1595
5. Maron B.J., McKenna W.J., Danielson G.K., et al., Task Force on Clinical Expert Consensus Documents, American College of Cardiology, Committee for Practice Guidelines, European Society of Cardiology. American College of Cardiology/European Society of Cardiology clinical expert consensus document on hypertrophic cardiomyopathy. A report of the American College of Cardiology Foundation Task Force on Clinical Expert Consensus Documents and the European Society of Cardiology Committee for Practice Guidelines. J Am Coll Cardiol 42 (2003) 1687-1713
6. Maron M.S., Olivotto I., Betocchi S., et al. Effect of left ventricular outflow tract obstruction on clinical outcome in hypertrophic cardiomyopathy. N Engl J Med 348 (2003) 295-303
7. Maron M.S., Olivotto I., Zenovich A.G., et al. Hypertrophic cardiomyopathy is predominantly a disease of left ventricular outflow tract obstruction. Circulation 114 (2006) 2232-2239
8. Nishimura R.A., Trusty J.M., Hayes D.L., et al. Dual-chamber pacing for hypertrophic cardiomyopathy: a randomized, double-blind, crossover trial. J Am Coll Cardiol 29 (1997) 435-441
9. Maron B.J., Nishimura R.A., McKenna W.J., Rakowski H., Josephson M.E., Kieval R.S., and M-PATHY Study Investigators. Assessment of permanent dual-chamber pacing as a treatment for drug-refractory symptomatic patients with obstructive hypertrophic cardiomyopathy. A randomized, double-blind, crossover study (M-PATHY). Circulation 99 (1999) 2927-2933
10. Morrow A.G., Reitz B.A., Epstein S.E., et al. Operative treatment in hypertrophic subaortic stenosis: techniques, and the results of pre and postoperative assessments in 83 patients. Circulation 52 (1975) 88-102
11. McCully R.B., Nishimura R.A., Tajik A.J., et al. Extent of clinical improvement after surgical treatment of hypertrophic obstructive cardiomyopathy. Circulation 94 (1996) 467-471
12. Maron B.J., Merrill W.H., Freier P.A., et al. Long-term clinical course and symptomatic status of patients after operation for hypertrophic subaortic stenosis. Circulation 57 (1978) 1205-1213
13. Cohn L.H., Trehan H., and Collins Jr. J.J. Long-term follow-up of patients undergoing myotomy/myectomy for obstructive hypertrophic cardiomyopathy. Am J Cardiol 70 (1992) 657-660
14. Schulte H.D., Bircks W.H., Loesse B., et al. Prognosis of patients with hypertrophic obstructive cardiomyopathy after transaortic myectomy. Late results up to twenty-five years. J Thorac Cardiovasc Surg 106 (1993) 709-717
15. Schulte H.D., Borisoc K., Gams E., et al. Management of symptomatic hypertrophic obstructive cardiomyopathy-long-term results after surgical therapy. Thorac Cardiovasc Surg 47 (1999) 213-218
16. Ten Berg J.M., Suttorp M.J., Knaepen P.F., et al. Hypertrophic obstructive cardiomyopathy. Initial results and long-term follow-up after Morrow septal myectomy. Circulation 90 (1994) 1781-1793
17. Heric B., Lytle B.W., Miller D.P., et al. Surgical management of hypertrophic obstructive cardiomyopathy. Early and late results. J Cardiovasc Surg 110 (1995) 195-206
18. Robbins R.C., and Stinson E.B. Long-term results of left ventricular myotomy and myectomy for obstructive hypertrophic cardiomyopathy. J Thorac Cardiovasc Surg 111 (1996) 586-594
19. Gol M.K., Emir M., Keles T., et al. Septal myectomy in hypertrophic obstructive cardiomyopathy: late results with stress echocardiography. Ann Thorac Surg 64 (1997) 739-745
20. Sigwart U. Non-surgical myocardial reduction for hypertrophic obstructive cardiomyopathy. Lancet 346 (1995) 211-214
21. Fernandes V.L., Nagueh S.F., Wang W., Roberts R., and Spencer III W.H. A prospective follow-up of alcohol septal ablation for symptomatic hypertrophic obstructive cardiomyopathy-the Baylor experience (1996-2002). Clin Cardiol 28 (2005) 124-130
22. Lakkis N.M., Nagueh S.F., Kleiman N.S., et al. Echocardiography-guided ethanol septal reduction for hypertrophic obstructive cardiomyopathy. Circulation 98 (1998) 1750-1755
23. Gietzen F.H., Leuner C.J., Raute-Kreinsen U., et al. Acute and long-term results after transcoronary ablation of septal hypertrophy (TASH). Catheter interventional treatment for hypertrophic obstructive cardiomyopathy. Eur Heart J 20 (1999) 1342-1354
24. Faber L., Meissner A., Ziemssen P., et al. Percutaneous transluminal septal myocardial ablation for hypertrophic obstructive cardiomopathy: long term follow-up of the first series of 25 patients. Heart 83 (2000) 326-331
25. Lakkis N.M., Nagueh S.F., Dunn J.K., et al. Non-surgical septal reduction therapy for hypertrophic obstructive cardiomyopathy: one-year follow-up. J Am Coll Cardiol 36 (2000) 852-855
26. Quinones M.A., Waggoner A.D., Reduto L.A., et al. A new, simplified and accurate method for determining ejection fraction with two-dimensional echocardiography. Circulation 64 (1981) 744-753
27. Maron B.J. Controversies in cardiovascular medicine. Surgical myectomy remains the primary treatment option for severely symptomatic patients with obstructive hypertrophic cardiomyopathy. Circulation 116 (2007) 196-206
28. Fifer M.A. Controversies in cardiovascular medicine. Most fully informed patients choose septal ablation over septal myectomy. Circulation 116 (2007) 207-216
29. Nagueh S.F., Ommen S.R., Lakkis N.M., et al. Comparison of ethanol septal reduction therapy with surgical myectomy for the treatment of hypertrophic obstructive cardiomyopathy. J Am Coll Cardiol 38 (2001) 1701-1706
30. Qin J.X., Shiota T., Lever H.M., et al. Outcome of patients with hypertrophic obstructive cardiomyopathy after percutaneous transluminal septal myocardial ablation and septal myectomy surgery. J Am Coll Cardiol 38 (2001) 1994-2000
31. Ralph-Edwards A., Woo A., McCrindle B.W., et al. Hypertrophic obstructive cardiomyopathy: comparison of outcomes after myectomy or alcohol ablation adjusted by propensity score. J Thorac Cardiovasc Surg 129 (2005) 351-358
32. Firoozi S., Elliott P.M., Sharma S., et al. Septal myotomy-myectomy and transcoronary septal alcohol ablation in hypertrophic obstructive cardiomyopathy. A comparison of clinical, haemodynamic and exercise outcomes. Eur Heart J 23 (2002) 1617-1624
33. van der Lee C., ten Cate F., Geleijnse M.L., et al. Percutaneous versus surgical treatment for patients with hypertrophic obstructive cardiomyopathy and enlarged anterior mitral valve leaflets. Circulation 112 (2005) 482-488
34. Maron B.J. Hypertrophic cardiomyopathy and sudden death: new perspectives on risk stratification and prevention with the implantable cardioverter-defibrillator. Eur Heart J 21 (2000) 1979-1983
35. Woo A., Williams W.G., Choi R., et al. Clinical and echocardiographic determinants of long-term survival after surgical myectomy in obstructive hypertrophic cardiomyopathy. Circulation 111 (2005) 2033-2041
36. Ommen S.R., Maron B.J., Olivotto I., et al. Long-term effects of surgical septal myectomy on survival in patients with obstructive hypertrophic cardiomyopathy. J Am Coll Cardiol 46 (2005) 470-476
37. Mazur W., Nagueh S.F., Lakkis N.M., et al. Regression of left ventricular hypertrophy after nonsurgical septal reduction therapy for hypertrophic obstructive cardiomyopathy. Circulation 103 (2001) 1492-1496
38. van Dockum W.G., Beek A.M., ten Cate F.J., et al. Early onset and progression of left ventricular remodeling after alcohol septal ablation in hypertrophic obstructive cardiomyopathy. Circulation 111 (2005) 2503-2508